From concept(ion) to life after death/the grave: the ‘natural’ history and life-cycle(s) of Novel Psychoactive Substances (NPS) by Orsolini, Laura et al.
Research Archive
Citation for published version:
Corkery JM, Orsolini L, Papanti D, and Schifano F., ‘From 
concept(ion) to life after death/the grave: The ‘natural’ 
history and life cycle(s) of novel psychoactive substances 
(NPS)’, Human Psychopharmacology: Clinical and 
Experimental, Vol. 32 (3):e2566, May 2017.
DOI: 
https://doi.org/10.1002/hup.2566
Document Version:
This is the Accepted Manuscript version.
The version in the University of Hertfordshire Research Archive 
may differ from the final published version.  Users should 
always cite the published version of record.
Copyright and Reuse: 
This article may be used for non-commercial purposes in 
accordance with Wiley Terms and Conditions for Self-Archiving.
Enquiries
If you believe this document infringes copyright, please contact the 
Research & Scholarly Communications Team at rsc@herts.ac.uk
For Peer Review
 
 
 
 
 
 
From concept(ion) to life after death/the grave: the 
‘natural’ history and life-cycle(s) of Novel Psychoactive 
Substances (NPS) 
 
 
Journal: Human Psychopharmacology: Clinical and Experimental 
Manuscript ID HUP-16-0058.R1 
Wiley - Manuscript type: Special issue on novel psychoactive substances 
Date Submitted by the Author: n/a 
Complete List of Authors: Corkery, John; University of Hertfordshire, Psychopharmacology, Drug 
Misuse and Novel Psychoactive Substances Research Unit 
Orsolini, Laura; University of Hertfordshire, Psychopharmacology, Drug 
Misuse and Novel Psychoactive Substances Research Unit 
Papanti, Duccio; University of Hertfordshire, Psychopharmacology, Drug 
Misuse and Novel Psychoactive Substances Research Unit 
Schifano, Fabrizio; University of Hertfordshire, Psychopharmacology, Drug 
Misuse and Novel Psychoactive Substances Research Unit 
Keyword: 
Novel Psychoactive Substances (NPS), life-cycle(s), natural history, 
monitoring 
  
 
 
http://mc.manuscriptcentral.com/hup
Human Psychopharmacology: Clinical and Experimental
For Peer Review
1 
 
From concept(ion) to life after death/the grave: the ‘natural’ history and life-cycle(s) of 
Novel Psychoactive Substances (NPS) 
 
 
Abstract:  
 
A range of information needs should be met in order to better understand and predict the 
longevity/existence of Novel Psychoactive Substances (NPS). This conceptual paper argues 
that one way of assessing how long a molecule may be around is to document how the life-
cycles or natural histories of ‘traditional’ drugs and NPS evolve. The earliest indication of the 
possible appearance of a new substance might be evidenced on the DeepWeb. However, this 
means they are less visible, in line with the clandestine nature of drug use and supply. 
Therefore, monitoring discussion groups/fora needs the development of new methods 
compared to those used in the Surface Net. Issues needing consideration in establishing NPS 
life-cycles are outlined here, together with the probable outcomes that could result. The 
approach advocated means that it should be easier to identify which NPS are likely to come 
up or are emerging in real time, and, therefore, pre-empt/prevent their supply.  
 
(153 words) 
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From concept(ion) to life after death/the grave: the ‘natural’ history and life-cycle(s) of Novel 
Psychoactive Substances (NPS) 
  
WHY DO WE NEED TO KNOW NOW ABOUT THE LONGEVITY/EXISTENCE OF 
NOVEL PSYCHOACTIVE SUBSTANCES (NPS)? 
 
New or novel psychoactive substances are not a recent phenomenon. In the latter decades of 
the twentieth century new psychoactive substances such as ecstasy (MDMA), ‘crack’ cocaine 
and methylamphetamine emerged onto the international recreational drug scene. However, 
during the first decade of the present century, the ‘noughties’, there was a marked step-
change in this phenomenon – an increasingly accelerated rate of appearance of new or novel 
substances contrasted with the substances above which are now part of the ‘traditional’ or 
established drug scene. Since 2005 this development has been accompanied by increases in 
the number and variety of molecules and products offered to (potential) consumers 
(EMCDDA-EUROPOL, 2016; UNODC, 2016). At present, there appears to be little prospect 
of the situation changing in the short-term. 
 
The accelerating speed and extent of these changes is causing a number of important 
challenges to various constituencies or stake-holders including: policy-makers, law 
enforcement agencies, treatment services, epidemiologists, communities and, not least of all, 
consumers. The key challenges are: how are NPS being created or ‘discovered’; what is 
appearing and when; are they related to existing known molecules; who is producing them 
and where; how are NPS being advertised and distributed; what is their legal status; what 
social consequences might arise; what are their likely properties; which and how many 
adverse health effects, morbidity or mortality can they cause; what the appropriate treatments 
are; what services might be impacted and how, and over what time-scale(s).   
 
Briefly, these challenges arise from the fact that most NPS are unknown quantities in that 
they have not been subject to any type(s) of prior testing; therefore, their psychoactive 
properties (if any), pharmacological, neurophysiological, neuropsychological, 
psychopharmacological, toxicological, and addiction potential attributes remain unclear. 
Furthermore, the contents of NPS/’legal high’ products offered for sale are unknown to law 
enforcement agencies, retailers, potential purchasers/consumers, health professionals, etc. and 
may change over time (Davies et al., 2010; Ramsey et al., 2010).  
 
The challenges thrown up by this lack of information make it difficult to know if it is 
necessary to respond to the emergence of a particular molecule and, if a response is 
considered appropriate, what form(s) that might take. Part of any strategy that needs to be in 
place for such considerations ought to include an assessment of how long that molecule may 
remain in circulation and what may be the possible consequences.  
 
One way of assessing how long a molecule may be around would be to compare its known 
characteristics with that of similar molecules and what happened to them. This means 
charting the existence of a number of psychoactive substances, including new or novel ones, 
in order to establish base-lines against which predictive models could be developed and 
tested. In other words, a series of life-cycles or natural histories of how ‘traditional’ 
recreational drugs and NPS evolve need to be documented.   
 
CONCEPTUAL APPROACH 
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A common approach in describing the stages in the production and consumption of goods is 
to look at their journey using such metaphors as “from field to fork” or “life is a journey” 
from “birth to death” or “cradle to grave”. In the psychoactive substances field, we developed 
a conceptual framework for classifying mortality associated with each stage of the khat plant's 
journey from its cultivation, transportation, consumption, to its effects on the human body. 
Specifically, we utilised evidence abstracted from observed phenomena derived from a range 
of sources along that journey to provide a vehicle to identify factors that may impact on the 
phenomenon of khat-related mortality (Corkery et al., 2011). 
 
It is now proposed that a similar approach could be applied to the phenomenon of 
psychoactive substances, both ‘traditional’ and ‘novel’/’new’. The aim would be to identify 
initially what the overall timeline and scale is for psychoactive substances, especially ‘legal 
highs’/novel psychoactive substances (NPS), from original concept or creation through to 
death (of human individuals), or even beyond, i.e. their survival, demise or change following 
regulation/control.  
 
So far as can be ascertained from internet searches using Google and Google Scholar, this is 
the first time this approach has been mooted in the published literature in the field of 
substance (ab)use. However, the notion of “cradle to grave” tracking or monitoring over the 
life cycle of investigational/experimental products is used in the field of pharmaceutics for 
accountability, reconciliation, destruction, etc. throughout a product’s life cycle (Ma et al., 
2007; Edwards, 2008). The word ‘g neration’ has been used in recent years to describe new 
psychoactive products and molecules created and released to replace those existing ones 
coming under control as a result of legislative actions.  
 
The term ‘drug epidemic cycle’ (Rose et al., 2015) has been used to describe the process by 
which a ‘recreational’ drug is first used within a narrowly-defined population or community 
before becoming main-stream (e.g. the use of methamphetamine in the ‘gay’ community 
before moving into the ‘club scene’) possibly because of its perceived safety, desired effects, 
and legality before leading to adverse health consequences, then controls, and perhaps leading 
to reduced consumption. However, this notion does not capture the possibility of re-
emergence. Furthermore, ‘epidemic’ is an inaccurate term in this context.  
 
ASPECTS TO COVER 
 
In the context of the EPS/NPS project (http://www.npsproject.eu/), the authors are involved in 
studying the role(s) of the Internet, especially the DeepWeb, in the creation, availability, sale, 
distribution of substances, and dissemination of information about NPS. The idea emerged 
during a ‘brain-storming’ session that the earliest indication of the possible appearance of a 
new substance might be evidenced on the DeepWeb, thereby giving a ‘heads-up’ or advance 
warning to relevant stake-holders. This thought was subsequently elaborated into the notion 
that there may be benefits in looking at the life-cycle or natural history/evolution of specific 
NPS. Key aspects to try and document include: first appearance on the DeepWeb; migration 
to the Surface Net/Internet; move into ‘head-shops’ and/or the ‘street’ market; notification to 
formal Early Warning Systems; implementation of legislation to counter the substance; 
effects of legislation/regulation on availability/use or displacement/substitution; and whether 
NPS suffer a demise, rebirth/reincarnation/resurrection or alteration/mutation/reinvention. 
Further details of these aspects and relevant resources are given in Table 1; this is not an 
exhaustive list. 
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HOW COULD THIS RESEARCH BE DONE? 
 
Both retrospective and prospective collection of data on NPS and other substances, including 
those already regulated/controlled would be required in order to get a complete profile of 
‘traditional’ and newly emerging/re-emerging psychoactive substances. Prospective data 
collection would have to be undertaken on a regular and systematic basis, perhaps with a 
periodicity as short as a week. 
 
We conjecture that data pointing to the existence of new NPS would first emerge on the 
DeepWeb - especially DeepNets - before appearing on the Surface Net (Internet) and will be 
less visible, in line with the clandestine nature of drug use and supply. Therefore, it might be 
sensible to monitor discussion groups/fora (across several domains/areas of interest – not just 
users) at specified intervals, say every 2 or 3 weeks, and to take copies/snap-shots of the 
sites/web-pages to see how things develop over time, and also to see how long it takes before 
substances are found on the Surface Net. 
 
Methods for online monitoring of the Internet developed by previous projects such as 
Psychonaut (Deluca et al., 2012), ReDNet (Corazza et al., (2013), and EU-MADNESS 
(http://www.eumadness.eu/) would need to be adapted and refined for DeepWeb monitoring 
as part of the Enhancing Police EPS/NPS project (http://www.npsproject.eu/) and any future 
work. The key difference would be the use of an Internet communication method intended to 
enable online anonymity such as TOR (https://www.torproject.org/) when monitoring the 
DeepWeb, and suitable search engines, e.g. grams 
(https://www.deepdotweb.com/2014/04/08/grams-darknetmarkets-search-engine/). Search 
strategies and search terms would need to be developed to monitor the different types of 
websites, open and hidden, as outlined in Table 1.  
 
Access to other data, including databases, professional networks, and access to informed 
stake-holders such as members of early warning systems would need to be developed and 
maintained so that detailed information relating to the data given in Table 1 can be collected 
on a systematic and routine basis. The types of data to be collected would need to be agreed 
by participating researchers and data-providers, along with data-sharing and confidentiality 
protocols, etc. Compilation of data from this multi-disciplinary approach should be centrally 
co-ordinated, and held in secure conditions with appropriate levels of access. 
 
The aim of the data collection would be to collect data that will lend themselves to the 
development of mathematical models that will validate existing and new knowledge of 
‘traditional’ recreational substances and facilitate predictions regarding the likely stages and 
time-scales in the life-cycles of NPS. 
 
LIKELY OUTCOMES OF SUCH RESEARCH 
 
There may be different time-scales for different types of ‘traditional’ and legal drugs as well 
as NPS. Old medicines discontinued because of adverse side-effects ‘rediscovered’ from 
scanning the patent databases may have a far longer life-story than newer/current medications 
being abused (e.g. modafinil) or new molecules created to avoid new regulations/controls 
(e.g. methylphenidate derivatives), but having a shorter history than natural products/plants 
used for centuries in folk-medicine/religious activities, etc.  
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This approach should make it faster to track the ‘historical evolution of an emerging NPS’. It 
could be possible to collect more information on a specified drug without waiting for its 
appearance. The potential insights that could be generated by the proposed approach cover 
five main domains. First, change over time in: developments in the uses, modes of 
administration, formulations/preparations, content of products, marketing, supply chains, 
prices, purities, quantities offered. Second, their first appearance on discussion fora/posts. 
Third, their first appearance on drug market sites. Fourth, how their 
markets/availability/attractiveness changes over time, and how these aspects change 
depending on legal status/notification in a specified country, etc. The legal status of specific 
molecules may differ in various countries, thereby leading to different patterns in terms of 
drug availability, use, treatment, etc. Lastly, health risks (acute and chronic physical/mental), 
morbidity, mortality associated with NPS (production and/or consumption).  
 
However, some considerations will need to be borne in mind. Many NPS appearing as 
‘products’ may be marketed with the same packaging but contain different compounds 
(Davies et al., 2010; Ramsey et al., 2010). Therefore, if data are only collected from websites 
without testing/verifying the chemical composition of these drugs, researchers could collect 
‘clinical’ and ‘marketing’ data not necessarily associated with an identified chemical 
composition (Hillebrand et al., 2010).  
 
CONCLUSIONS 
 
Taking a holistic approach to NPS allows researchers to identify/think of wider range of 
dimensions of a phenomenon and what factors may impact on it and how these might be 
influenced/ tackled in the future if desired/thought practical in order to affect changes. There 
will be implications for service provision, treatment options, interdiction, monitoring/ 
surveillance, pharmacovigilance, epidemiology, law-making, education, etc. The approach 
advocated here should mean that it could be easier to identify which NPS are likely to come 
up or are emerging in real time, and, therefore, pre-empt/prevent their supply. The lag which 
academic research currently experiences in respect of the online NPS market (Deluca et al., 
2012) should be reduced.  
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Table 1. Aspects/dimensions that could be considered by a ‘life-cycle’/’natural history’ 
approach to the study of NPS and relevant resources 
 
Aspect/dimension Resources needed for data collection and analysis  
Hidden developments 
Original idea/concept/source for molecule DeepWeb discussions amongst ‘research chemists’: The idea may be completely 
original as in creating a ‘brand new’ unique molecule or ‘rediscovering’ molecules 
in old patents (e.g. AH7941, MT-45), etc. 
Creation of a name for molecule/product DeepWeb activity monitoring 
Offering for sale/advertising DeepWeb activity  monitoring; ‘test purchases’; Law enforcement interdiction; 
Mention in user discussion groups/fora DeepWeb activity  monitoring  
Emergence into common view 
Appearance on surface net/in head shops etc. Internet/media monitoring 
Offers for sale/advertising Internet/media monitoring; test purchasing; law enforcement interdiction; 
Mention in user discussion groups/fora Internet/media monitoring  
Reports to treatment services Mental health and drug service clients reports use of NPS 
Health concerns 
Intoxications Media reports; ambulance/ paramedic call-outs; presentations to Emergency 
Departments; 
Severe adverse health consequences Admissions to general hospital wards; psychiatric in-patient treatment; mental 
health and drug treatment service clients request help for problems caused by NPS; 
Calls to National Poison Information Services/ Toxbase inquiries;  
Health Professional concerns ‘Health alerts’ issued; case reports in medical literature/ blogs; case series in 
medical literature; 
Fatalities Inquests/ Fatal Accident Inquiries (about 6 months after he event in the UK) or 
other judicial investigations; inclusion in official mortality statistics; 
Forensic detections 
Unknown NPS in toxicology screenings Amnesty bins; law enforcement drug confiscations; ‘test purchases’; biological 
samples – drug driving, work-place testing, hospital admissions, post-mortem 
investigations; 
Forensic professional concerns Reports in chemical, toxicological, forensic, pathological blogs/ literature; 
Social concerns 
Reports of ‘incidents’ Media reports, reports to police, local authorities (e.g. trading standards); concerns 
expressed by ‘interest’ groups; etc. 
Coverage in surveys Inclusion of suitable questions in surveys of different population groups, both 
paper-based and electronic, whether online or face to face any of the following 
scenarios – music concerts/ festivals, etc.; presentations to health professionals; 
arrest and imprisonment; etc. 
Official responses 
Risk assessments Local (administrative areas), national (country), international – European Union, 
WHO. 
Temporary regulation/control Local (administrative areas), national (country), international – European Union, 
INCB 
Permanent regulation/control Local (administrative areas), national (country), international – European Union, 
WHO & UNODC  
Advice on treatment Guidance issued by health professionals’ bodies; WHO 
Advice on forensic/chemical analyses Guidance from international professional associations; UNODC 
Advice on medical classification Guidance from Euro-Stat/WHO on ICD coding (advice needed for ICD10 and 11) 
Effects of regulation/control Availability, price, purity, hospital admissions, deaths, demand for treatment, etc. 
Long-term monitoring Prevalence, emergence of health harms from long-term use; Advice on monitoring 
from EMCDDA and UNODC  
Acronyms: EMCDDA – European Monitoring Centre for Drugs and Drug Addiction; ICD – International Classification of Diseases; INC 
– International Narcotics Control Board; UNODC – United Nations Office for Drugs and Crime;  WHO – World Health Organization; 
UNODC 
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From concept(ion) to life after death/the grave: the ‘natural’ history and life-cycle(s) of Novel 
Psychoactive Substances (NPS) 
  
WHY DO WE NEED TO KNOW NOW ABOUT THE LONGEVITY/EXISTENCE OF 
NOVEL PSYCHOACTIVE SUBSTANCES (NPS)? 
 
New or novel psychoactive substances are not a recent phenomenon. In the latter decades of 
the twentieth century new psychoactive substances such as ecstasy (MDMA), ‘crack’ cocaine 
and methylamphetamine emerged onto the international recreational drug scene. The 
phenethylamine 2C-T-7, first synthesised in 1986, was described in detail in the Shulgins’ 
PIKHAL book (Shulgin & Shulgin, 1991) leading to dissemination of data relating to it. By 
1997 it was possible to purchase this compound from Dutch and German ‘smart’ shops. 
Street-level availability was very low by the early 2000s, but a survey of internet websites 
indicated a somewhat different scenario both in terms of information about it and 
opportunities for purchase Schifano et al., 2005). Since 2005 there have been only occasional 
confiscations and case-reports or academic papers concerning 2C-T-7.  
 
However, during the first decade of the present century, the ‘noughties’, there was a marked 
step-change in this phenomenon – an increasingly accelerated rate of appearance of new or 
novel substances contrasted with the substances above which are now part of the ‘traditional’ 
or established drug scene. Since 2005 this development has been accompanied by increases in 
the number and variety of molecules and products offered to (potential) consumers 
(EMCDDA-EUROPOL, 2016; UNODC, 2016). At present, there appears to be little prospect 
of the situation changing in the short-term. 
 
The accelerating speed and extent of these changes is causing a number of important 
challenges to various constituencies or stake-holders including: policy-makers, law 
enforcement agencies, treatment services, epidemiologists, communities and, not least of all, 
consumers. The key challenges are: how are NPS being created or ‘discovered’; what is 
appearing and when; are they related to existing known molecules; who is producing them 
and where; how are NPS being advertised and distributed; what is their legal status; what 
social consequences might arise; what are their likely properties; which and how many 
adverse health effects, morbidity or mortality can they cause; what the appropriate treatments 
are; what services might be impacted and how, and over what time-scale(s).   
 
Briefly, these challenges arise from the fact that most NPS are unknown quantities in that 
they have not been subject to any type(s) of prior testing; therefore, their psychoactive 
properties (if any), pharmacological, neurophysiological, neuropsychological, 
psychopharmacological, toxicological, and addiction potential attributes remain unclear. 
Furthermore, the contents of NPS/’legal high’ products offered for sale are unknown to law 
enforcement agencies, retailers, potential purchasers/consumers, health professionals, etc. and 
may change over time (Davies et al., 2010; Ramsey et al., 2010).  
 
The challenges thrown up by this lack of information make it difficult to know if it is 
necessary to respond to the emergence of a particular molecule and, if a response is 
considered appropriate, what form(s) that might take. Part of any strategy that needs to be in 
place for such considerations ought to include an assessment of how long that molecule may 
remain in circulation and what may be the possible consequences.  
 
Page 9 of 15
http://mc.manuscriptcentral.com/hup
Human Psychopharmacology: Clinical and Experimental
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
2 
 
One way of assessing how long a molecule may be around would be to compare its known 
characteristics with that of similar molecules and what happened to them. This means 
charting the existence of a number of psychoactive substances, including new or novel ones, 
in order to establish base-lines against which predictive models could be developed and 
tested. In other words, a series of life-cycles or natural histories of how ‘traditional’ 
recreational drugs and NPS evolve need to be documented.   
 
CONCEPTUAL APPROACH 
 
A common approach in describing the stages in the production and consumption of goods is 
to look at their journey using such metaphors as “from field to fork” or “life is a journey” 
from “birth to death” or “cradle to grave”. In the psychoactive substances field, we developed 
a conceptual framework for classifying mortality associated with each stage of the khat plant's 
journey from its cultivation, transportation, consumption, to its effects on the human body. 
Specifically, we utilised evidence abstracted from observed phenomena derived from a range 
of sources along that journey to provide a vehicle to identify factors that may impact on the 
phenomenon of khat-related mortality (Corkery et al., 2011). 
 
It is now proposed that a similar approach could be applied to the phenomenon of 
psychoactive substances, both ‘traditional’ and ‘novel’/’new’. The aim would be to identify 
initially what the overall timeline and scale is for psychoactive substances, especially ‘legal 
highs’/novel psychoactive substances (NPS), from original concept or creation through to 
death (of human individuals), or even beyond, i.e. their survival, demise or change following 
regulation/control.  
 
So far as can be ascertained from internet searches using Google and Google Scholar, this is 
the first time this approach has been mooted in the published literature in the field of 
substance (ab)use. However, the notion of “cradle to grave” tracking or monitoring over the 
life cycle of investigational/experimental products is used in the field of pharmaceutics for 
accountability, reconciliation, destruction, etc. throughout a product’s life cycle (Ma et al., 
2007; Edwards, 2008). The word ‘generation’ has been used in recent years to describe new 
psychoactive products and molecules created and released to replace those existing ones 
coming under control as a result of legislative actions.  
 
The term ‘drug epidemic cycle’ (Rose et al., 2015) has been used to describe the process by 
which a ‘recreational’ drug is first used within a narrowly-defined population or community 
before becoming main-stream (e.g. the use of methamphetamine in the ‘gay’ community 
before moving into the ‘club scene’) possibly because of its perceived safety, desired effects, 
and legality before leading to adverse health consequences, then controls, and perhaps leading 
to reduced consumption. However, this notion does not capture the possibility of re-
emergence. Furthermore, ‘epidemic’ is an inaccurate term in this context.  
 
ASPECTS TO COVER 
 
In the context of the EPS/NPS project (http://www.npsproject.eu/), the authors are involved in 
studying the role(s) of the Internet, especially the DeepWeb, in the creation, availability, sale, 
distribution of substances, and dissemination of information about NPS. The idea emerged 
during a ‘brain-storming’ session that the earliest indication of the possible appearance of a 
new substance might be evidenced on the DeepWeb, thereby giving a ‘heads-up’ or advance 
warning to relevant stake-holders. This thought was subsequently elaborated into the notion 
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that there may be benefits in looking at the life-cycle or natural history and evolution of 
specific NPS. Key aspects to try and document include: first appearance on the DeepWeb; 
migration to the Surface Net or open Internet; move into ‘head-shops’ and/or the ‘street’ 
market; notification to formal Early Warning Systems; implementation of legislation to 
counter the substance; effects of legislation/regulation on availability/use or 
displacement/substitution; and whether NPS suffer a demise, 
rebirth/reincarnation/resurrection or alteration/mutation/reinvention. Further details of these 
aspects and relevant resources are given in Table 1; this is not an exhaustive list. 
 
HOW COULD THIS RESEARCH BE DONE? 
 
Both retrospective and prospective collection of data on NPS and other substances, including 
those already regulated or controlled would be required in order to get a complete profile of 
‘traditional’ and newly emerging/re-emerging psychoactive substances. Prospective data 
collection would have to be undertaken on a regular and systematic basis, perhaps with a 
periodicity as short as a week. 
 
We conjecture that data pointing to the existence of new NPS would first emerge on the 
DeepWeb - especially DeepNets - before appearing on the Surface Net (Internet) and will be 
less visible, in line with the clandestine nature of drug use and supply. Therefore, it might be 
sensible to monitor discussion groups/fora (across several domains/areas of interest – not just 
users) at specified intervals, say every 2 or 3 weeks, and to take copies/snap-shots of the 
sites/web-pages to see how things develop over time, and also to see how long it takes before 
substances are found on the Surface Net. 
 
Methods for online monitoring of the Internet developed by previous projects such as 
Psychonaut (Deluca et al., 2012), ReDNet (Corazza et al., (2013), and EU-MADNESS 
(http://www.eumadness.eu/) would need to be adapted and refined for DeepWeb monitoring 
as part of the Enhancing Police EPS/NPS project (http://www.npsproject.eu/) and any future 
work. The key difference would be the use of an Internet communication method intended to 
enable online anonymity such as TOR (https://www.torproject.org/) when monitoring the 
DeepWeb, and suitable search engines, e.g. grams 
(https://www.deepdotweb.com/2014/04/08/grams-darknetmarkets-search-engine/). Search 
strategies and search terms would need to be developed to monitor the different types of 
websites, open and hidden, as outlined in Table 1.  
 
Access to other data, including databases, professional networks, and access to informed 
stake-holders such as members of early warning systems would need to be developed and 
maintained so that detailed information relating to the data given in Table 1 can be collected 
on a systematic and routine basis. The types of data to be collected would need to be agreed 
by participating researchers and data-providers, along with data-sharing and confidentiality 
protocols, etc. Compilation of data from this multi-disciplinary approach should be centrally 
co-ordinated, and held in secure conditions with appropriate levels of access. 
 
The aim of the data collection would be to collect data that will lend themselves to the 
development of mathematical models that will validate existing and new knowledge of 
‘traditional’ recreational substances and facilitate predictions regarding the likely stages and 
time-scales in the life-cycles of NPS. 
 
LIKELY OUTCOMES OF SUCH RESEARCH 
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There may be different time-scales for different types of ‘traditional’ and legal drugs as well 
as NPS. Old medicines discontinued because of adverse side-effects ‘rediscovered’ from 
scanning the patent databases may have a far longer life-story than newer/current medications 
being abused (e.g. modafinil) or new molecules created to avoid new regulations/controls 
(e.g. methylphenidate derivatives), but having a shorter history than natural products/plants 
used for centuries in folk-medicine/religious activities, etc.  
 
This approach should make it faster to track the ‘historical evolution of an emerging NPS’. It 
could be possible to collect more information on a specified drug without waiting for its 
appearance. The potential insights that could be generated by the proposed approach cover 
five main domains. First, change over time in: developments in the uses, modes of 
administration, formulations/preparations, content of products, marketing, supply chains, 
prices, purities, quantities offered. Second, their first appearance on discussion fora/posts. 
Third, their first appearance on drug market sites. Fourth, how their 
markets/availability/attractiveness changes over time, and how these aspects change 
depending on legal status/notification in a specified country, etc. The legal status of specific 
molecules may differ in various countries, thereby leading to different patterns in terms of 
drug availability, use, treatment, etc. Lastly, health risks (acute and chronic physical/mental), 
morbidity, mortality associated with NPS (production and/or consumption).  
 
However, some considerations will need to be borne in mind. Many NPS appearing as 
‘products’ may be marketed with the same packaging but contain different compounds 
(Davies et al., 2010; Ramsey et al., 2010). In addition, the same ‘branded’ compound may 
contain different NPS or concentrations in different countries and/or at different times 
(Corazza et al., 2014). Therefore, if data are only collected from websites without 
testing/verifying the chemical composition of these drugs, researchers could collect ‘clinical’ 
and ‘marketing’ data not necessarily associated with an identified chemical composition 
(Hillebrand et al., 2010).  
 
CONCLUSIONS 
 
Taking a holistic approach to NPS allows researchers to identify/think of wider range of 
dimensions of a phenomenon and what factors may impact on it and how these might be 
influenced/ tackled in the future if desired/thought practical in order to affect changes. There 
will be implications for service provision, treatment options, interdiction, monitoring/ 
surveillance, pharmacovigilance, epidemiology, law-making, education, etc. The approach 
advocated here should mean that it could be easier to identify which NPS are likely to come 
up or are emerging in real time, and, therefore, pre-empt/prevent their supply. The lag which 
academic research currently experiences in respect of the online NPS market (Deluca et al., 
2012) should be reduced.  
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Table 1. Aspects/dimensions that could be considered by a ‘life-cycle’/’natural history’ 
approach to the study of NPS and relevant resources 
 
Aspect/dimension Resources needed for data collection and analysis  
Hidden developments 
Original idea/concept/source for molecule DeepWeb discussions amongst ‘research chemists’: The idea may be completely 
original as in creating a ‘brand new’ unique molecule or ‘rediscovering’ molecules 
in old patents (e.g. AH7941, MT-45), etc. 
Creation of a name for molecule/product DeepWeb activity monitoring 
Offering for sale/advertising DeepWeb activity  monitoring; ‘test purchases’; Law enforcement interdiction; 
Mention in user discussion groups/fora DeepWeb activity  monitoring  
Emergence into common view 
Appearance on surface net/in head shops etc. Internet/media monitoring 
Offers for sale/advertising Internet/media monitoring; test purchasing; law enforcement interdiction; 
Mention in user discussion groups/fora Internet/media monitoring  
Reports to treatment services Mental health and drug service clients reports use of NPS 
Health concerns 
Intoxications Media reports; ambulance/ paramedic call-outs; presentations to Emergency 
Departments; 
Severe adverse health consequences Admissions to general hospital wards; psychiatric in-patient treatment; mental 
health and drug treatment service clients request help for problems caused by NPS; 
Calls to National Poison Information Services/ Toxbase inquiries;  
Health Professional concerns ‘Health alerts’ issued; case reports in medical literature/ blogs; case series in 
medical literature; 
Fatalities Inquests/ Fatal Accident Inquiries (about 6 months after he event in the UK) or 
other judicial investigations; inclusion in official mortality statistics; 
Forensic detections 
Unknown NPS in toxicology screenings Amnesty bins; law enforcement drug confiscations; ‘test purchases’; biological 
samples – drug driving, work-place testing, hospital admissions, post-mortem 
investigations; 
Forensic professional concerns Reports in chemical, toxicological, forensic, pathological blogs/ literature; 
Social concerns 
Reports of ‘incidents’ Media reports, reports to police, local authorities (e.g. trading standards); concerns 
expressed by ‘interest’ groups; etc. 
Coverage in surveys Inclusion of suitable questions in surveys of different population groups, both 
paper-based and electronic, whether online or face to face any of the following 
scenarios – music concerts/ festivals, etc.; presentations to health professionals; 
arrest and imprisonment; etc. 
Official responses 
Risk assessments Local (administrative areas), national (country), international – European Union, 
WHO. 
Temporary regulation/control Local (administrative areas), national (country), international – European Union, 
INCB 
Permanent regulation/control Local (administrative areas), national (country), international – European Union, 
WHO & UNODC  
Advice on treatment Guidance issued by health professionals’ bodies; WHO 
Advice on forensic/chemical analyses Guidance from international professional associations; UNODC 
Advice on medical classification Guidance from Euro-Stat/WHO on ICD coding (advice needed for ICD10 and 11) 
Effects of regulation/control Availability, price, purity, hospital admissions, deaths, demand for treatment, etc. 
Long-term monitoring Prevalence, emergence of health harms from long-term use; Advice on monitoring 
from EMCDDA and UNODC  
Acronyms: EMCDDA – European Monitoring Centre for Drugs and Drug Addiction; ICD – International Classification of Diseases; INC 
– International Narcotics Control Board; UNODC – United Nations Office for Drugs and Crime;  WHO – World Health Organization; 
UNODC 
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